Affymax And Takeda Report Long-Term Safety And Effectiveness Data Of Hematide In Chronic Renal Failure Patients With Anemia

Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development announced data from their ongoing Phase 2 trial to assess the long-term safety and tolerability of Hematide?, a potential treatment of anemia. These data showed that Hematide, dosed once every four weeks, successfully maintained mean hemoglobin levels between 11 and 12 g/dL for up to 18 months in hemodialysis patients who previously were treated with epoetin alfa. Hematide appeared generally well-tolerated.

More: continued here

Filed under: Urology on April 8th, 2008